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Background: Several studies showed an association between lung function and hypertension.
However, it must be considered that antihypertensive treatment might have an effect on lung
function, too. So far, this potential effect of antihypertensive medication on lung function has
been investigated mainly in patients with already existing pulmonary diseases. Thus, the aim
of this analysis was to determine whether hypertension and its medical treatment are associ-
ated with lung function impairment in a general adult population.
Methods: Within the cross-sectional study ECRHS-I Erfurt 1158 adults aged between 20 and 65
years performed lung function tests and blood pressure measurements. Additionally, informa-
tion on anthropometric measurements, sociodemographic characteristics and medical history
was available. Multivariate regression models were applied to study the association between
lung function, blood pressure and antihypertensive treatment.
Results: The combination of high blood pressure and the use of antihypertensive medication
had the strongest negative effect on lung function. Thus, it was associated with a deterioration
in FEV1 of 150 ml (pZ 0.01) and in FVC of 190 ml (p< 0.01). When using both high blood
pressure and antihypertensive medication as individual variables in one regression model, only
medication decreased FEV1 and FVC significantly (each p< 0.01).Center Munich, National Research Center for Environmental Health, Institute of Epidemiology,
herberg, Germany. Tel.: þ 49 89 3187 2952; fax: þ 49 89 3187 3380.
tz-muenchen.de (E. Schnabel).
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728 E. Schnabel et al.Conclusions: We speculate that high blood pressure in combination with antihypertensive
treatment and not HBP itself might be associated with reduced lung function in a general adult
population. Nevertheless, it must be considered that antihypertensive medication might just
be an indicator for very high blood pressure.
ª 2011 Elsevier Ltd. All rights reserved.Figure 1 ECRHS-I Erfurt.Background
Chronic obstructive pulmonary disease (COPD) has become
one of the major public health problems worldwide. It is
a leading cause for chronic morbidity and mortality and is
oftenassociatedwith awide variety of other chronic systemic
diseases.1 These comorbidities, including cardiovascular
diseases, diabetes, osteoporosis, skeletal muscle abnormal-
ities and cancer, markedly affect health outcomes in COPD.2
Thus, cardiovascular diseases and lung cancer are the most
common causes of death in mild or moderate COPD.3
Although the physiological interactions between respi-
ratory and cardiovascular system are not fully understood,
possibly chronic systemic and pulmonary inflammation play
an important role, several studies could show that lung
function and cardiovascular diseases are clearly
associated.4e11 The Framingham Study found an inverse
relationship between forced vital capacity (FVC) and
cardiovascular diseases and mortality, particular in
women.6 Moreover, it could be shown that FVC is a strong,
inverse predictor for the development of hypertension.8,9
Further studies also demonstrated that reduced pulmo-
nary function, including both low forced vital capacity
(FVC) and low forced expiratory volume in one second
(FEV1), was related to coronary heart diseases and hyper-
tension.5,7,11 Beyond, some studies indicated that the
combination of hypertension and low FEV1 was associated
with higher rates of cardiovascular diseases and death.4,10
Aside from the fact that chronic diseases that frequently
develop with COPD may contribute to its clinical manifes-
tation and severity, it has to be considered that the treat-
ment of these comorbidities might affect health outcomes in
COPD, too.12 For example beta-blocker therapy, which has
a proven mortality benefit in patients with hypertension,
heart failure and coronary heart disease, has been consid-
ered contraindicated in patients with asthma or COPD, as it
may produce bronchoconstriction and thereby worsen
respiratory flows and symptoms in these patients.13e15
However, the association between blood pressure, anti-
hypertensive treatment and impaired lung function has been
investigated mainly in patients with already existing pulmo-
nary diseases and less often in a population-based setting.
Thus, the aim of this analysis was to determine whether
hypertension and its medical treatment are associated with




The cross-sectional study ECRHS-I Erfurt (European
Community Respiratory Health Survey) was performed from1990 to 1992 in Erfurt, Germany; its design has been
described in detail in other studies.16,17 In a two-step
approach 6291 randomly chosen individuals from the Erfurt
population were asked to reply to a short questionnaire on
respiratory symptoms, which was sent by post (stage I).
Afterwards a population-based random sample of 2500 out
of the 4332 stage I responders was invited to attend a clin-
ical examination, to perform lung function measurement
and to answer a detailed questionnaire (stage II). The age
range covered subjects between 20 and 65 years. In stage
II, 1282 subjects underwent the clinical examination and
answered the detailed questionnaire, and 1162 lung func-
tion tests were available (see Fig. 1).
The study protocol has been approved by the Local Ethics
Committees of the Medical Academy in Erfurt and written
informed consent was obtained from all participants.
Outcome assessment
Lung function
All lung function tests were conducted based on the ECRHS
protocol.18 FVC and FEV1 were determined by spirometry in
all subjects, who did not smoke or use inhalers within 1 h
prior to the test. Tests were assumed as valid if at least two
technically satisfactory maneuvers were obtained within
a maximum of 9 trials. Based on the best maneuver as
defined by the highest sum of FVC and FEV1, the final values
of FVC and FEV1 were determined. Percent predicted
values were calculated according Quanjer et al.19
Blood pressure, medication and other determinants
Blood pressure was measured using a calibrated sphygmo-
manometer. Two independent blood pressure
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of 5 min in a sitting position. The mean of the two
measurements was used for the current analyses.20
Hypertension was defined as blood pressure 140 mmHg
systolic or 90 mmHg diastolic. Additionally, anthropometric
measurements, computer-assisted standardized interviews
and questionnaires on lifestyle and health related factors,
respiratory symptoms and use of medication were per-
formed. The smoking status (never, former or current
smokers) was assessed by self-report. Education level was
defined by the highest graduation (less than ordinary level,
ordinary level and more than ordinary level, ordinary level
is equivalent to a secondary school leaving certificate).
Furthermore, participants were asked whether they use
any antihypertensive medication. No detailed information
on the kind of medication is available. The following mutual
exclusive groups of high blood pressure (HBP) based on the
blood pressure measurement (HBP 140/90 mmHg) and
antihypertensive medication were defined:
- Group 1. No HBP, no medication: reference group
- Group 2. HBP and medication: high blood pressure and
the use of antihypertensive medication; treated but
uncontrolled hypertension
- Group 3. Only HBP: high blood pressure, but no anti-
hypertensive medication; untreated hypertension
- Group 4. Only medication: antihypertensive medica-
tion, but no high blood pressure; treated and controlled
hypertensionStatistical analyses
A comparison of lung function parameters and potential
determinants between the four mutual exclusive groups of
high blood pressure and antihypertensive medication, as
described above, was done using chi-square and Krus-
kaleWallis test. Furthermore, the association between lung
function and the groups of HBP antihypertensive medica-
tion was analyzed after stratification for doctor-diagnosed
asthma and smoking status. In addition to that a sensitivity
analysis of different blood pressure categories (<140/90;
140e159/90e99; 160e179/100e109; 180/110 mmHg) was
performed.
Multivariate regression models were applied to study the
association between HBP, antihypertensive medication and
lung function. Two models each were developed for the two
lung function parameters FEV1 and FVC. For the first model
the above mentioned mutual exclusive groups of HBP and
antihypertensive medication were used. Lung function in
treated but uncontrolled hypertensive (group 1), in
untreated hypertensive (group 2) and in treated and
controlled hypertensive subjects (group3) was compared to
lung function in subjects with no HBP using no antihyper-
tensive medication (group 4, reference group). For the
second model HBP and antihypertensive medication were
used as individual variables in one regression model to
analyse the possible combined effect of both. Results were
presented as estimates of lung volume reduction with
standard deviation (SD) and p-value. Adjustment was done
for the a priori defined potential confounding factors
gender, age, height, BMI, education level, packyears andrespiratory symptoms (cough and sputum production for at
least 3 months per year). p-values< 0.05 were considered
statistically significant for all analysis. All statistical anal-
ysis was performed with SAS, version 9.13.
Results
Complete data on hypertension and lung function was
available for 1158 subjects. Table 1 shows the comparison of
lung function parameters and potential confounders
between the above mentioned mutual exclusive groups of
HBP and antihypertensive medication. Subjects with HBP
despite the use of antihypertensive medication were
considerably older andhadahigher BMI compared toall other
groups (each p-value< 0.01). In women the HBP was more
often effectively treated with antihypertensive medication
compared tomen (p-valueZ 0.07), whereas in men HBP was
more frequently not treated at all (p-value< 0.01).
Furthermore, people with a low education level had
considerably more often HBP, regardless of whether it was
treated or not (each p-value< 0.01). Themean systolic (SBP)
and diastolic (DBP) blood pressure was highest in subjects
with treated, but uncontrolled HBP (p-value< 0.01).
The comparison of the lung function values pointed out,
that FEV1 % predicted (102.7 22.2 and 101.7 16.8,
respectively) and FVC % predicted (107.5 18.0 and
106.4 16.2, respectively) were considerably lower in
subjects with treated, but uncontrolled HBP, and in subjects
with treated and controlled HBP. In contrast, subjects with
HBP using no antihypertensive medication had comparable
FEV1 % predicted (107.5 15.6 compared to 107.1 14.4)
and FVC % predicted values (110.4 15.0 compared to
111.2 13.7) to subjectswith noHBP. Similar results could be
shown after stratification for doctor-diagnosed asthma in the
non-asthmatics, too. A further stratified analysis by smoking
status likewise revealed that FEV1 and FVC% predicted values
were reduced in subjects with treated HBP, regardless of
whether it was controlled or uncontrolled. However, current
smokers showed the lowest values compared to former or
never smokers.
A sensitivity analysis of different blood pressure cate-
gories indicated that only a very high blood pressure (180/
110 mmHg) was associated with significant lower FEV1
(pZ 0.01) and FVC % predicted values (pZ 0.05). A further
analysis in patients with blood pressure 180/110 mmHg
showed that FEV1 and FVC % predicted values were lower in
patients using blood pressure medication compared to
those using no medication. However, this was only signifi-
cant for FVC % predicted (pZ 0.05).
The application of multivariate regression models
pointed out that the combination of HBP and the use of
antihypertensive medication had the strongest negative
effect on lung function after adjusting for sex, age, BMI,
education level, packyears, and respiratory symptoms, as
cough and sputum production for at least 3 months per year
(Table 2). Thus, we observed a deterioration in FEV1 of
150 mL and in FVC of 190 mL among treated, but not
controlled hypertensive subjects compared to subjects with
no HBP and no antihypertensive medication (pZ 0.01 and
p< 0.01, respectively). When using both HBP and antihy-
pertensive medication as individual variables in one
regression model, it could be shown, that only the use of
Table 1 Comparison of lung function and potential determinants between high blood pressure groups and normotensives.
Group 1 (NZ 702) Group 2 (NZ 121) Group 3 (NZ 302) Group 4 (NZ 33) p-Value
No HBP, no medicationa HBP and medicationa Only HBP Only medicationa
Mean SD Mean SD Mean SD Mean SD
Lung function
FEV1 (l) 3.7 0.9 3.0 0.9 3.6 0.9 3.0 0.7 <0.01
FVC (l) 4.5 1.0 3.8 1.1 4.5 1.1 3.8 0.8 <0.01
FEV1 % predicted 107.1 14.4 102.7 22.2 107.5 15.6 101.7 16.8 <0.01
FVC % predicted 111.2 13.7 107.5 18.0 110.4 15.0 106.4 16.2 0.03
Blood pressure
SBP (mmHg) 124.1 9.5 163.3 18.6 150.2 15.6 130.6 6.4 <0.01
DBP (mmHg) 78.9 6.9 98.7 10.6 94.5 8.8 80.2 6.3 <0.01
Age (years) 38.0 11.4 53.0 8.7 45.7 11.6 48.2 11.0 <0.01
BMI (kg/m2) 24.0 3.5 28.3 3.9 26.8 4.1 25.5 3.6 <0.01
Packyears (y) 6.5 9.6 8.5 12.6 9.4 13.7 7.7 9.8 0.55
n (%) n (%) n (%) n (%)
Gender
Men 332 (47.3) 56 (46.3) 199 (65.9) 12 (36.4)
Women 370 (52.7) 65 (53.7) 103 (34.1) 21 (63.6)
p-Value <0.01 0.21 <0.01 0.07
Smoking status
Never 289 (41.2) 60 (49.6) 127 (42.1) 13 (39.4)
Former 145 (20.7) 35 (28.9) 84 (27.8) 12 (36.4)
Current 268 (38.2) 26 (21.5) 91 (30.1) 8 (24.2)
p-Value <0.01 0.01 0.11 0.20
Education
Low 268 (38.2) 93 (76.9) 161 (53.3) 23 (69.7)
Medium 270 (38.5) 12 (9.9) 81 (26.8) 8 (24.2)
High 164 (23.4) 16 (13.2) 60 (19.9) 2 (6.1)
p-Value <0.01 <0.01 0.04 0.02
Respiratory symptoms
Cough 49 (7.1) 13 (10.8) 38 (12.8) 2 (6.1)
Sputum production 23 (3.3) 15 (12.4) 31 (10.4) 0 (0)
HBPZ high blood pressure (140/90 mmHg); SBPZ systolic blood pressure; DBPZ diastolic blood pressure; FEV1: forced expiratory
volume in one second; FVC: forced vital capacity.
a Medication: antihypertensive medication; % predicted values according to Quanjer. Mean values standard deviation.
730 E. Schnabel et al.blood pressure medication had a significant association
with lower FEV1 and FVC values (each p< 0.01).Discussion
The present analyses of a population-based study demon-
strate that HBP in combination with the use of antihyper-
tensive medication is significantly associated with lower
FEV1 and FVC values. HBP regardless of its medical treat-
ment, however, is not associated with reduced lung
function.
Several studies showed an inverse association between
hypertension and lung function.5,7,11 However, it has to be
considered that most of these studies defined hypertension
as elevated blood pressure or use of antihypertensive
medication. Therefore, they did not distinguish between
the effect of high blood pressure and the effect ofantihypertensive medication on lung function. One study,
however, could show that FEV1 and FVC did not differ
between hypertensive subjects that used or did not use
beta blocking antihypertensives.7 But, the authors did not
analyse the effect of antihypertensive medication inde-
pendent of hypertension on lung function.
Thus, the question arises whether high blood pressure or
antihypertensive medication is the cause for reduced lung
function. Within observations studies it is difficult to distin-
guish between these two potential causes. Also from the
pathophysiological perspective the mechanism underlying
the possible relation between hypertension, its medication
and lung function is not fully understood and in the literature
there is support for both theories.5,9 One possible hypothesis
is that chronic hypertension causes left ventricular
dysfunction, which again results in elevated left atrial
pressure. This in turn might lead to an elevation of pulmo-
nary artery pressure, an increase in interstitial edema in the
Table 2 Association between high blood pressure, antihypertensive medication and lung function e results of the multivariate
regression analysis.
Variable Estimate SD p-Valueb Variable Estimate SD p-Valueb
Models for FEV1 Models for FVC
Model with mutual exclusive categories Model with mutual exclusive categories
No HBP, no medicationa No HBP, no medicationa
HBP and medication 0.15 0.05 0.01 HBP and medication 0.19 0.06 <0.01
Only HBP 0.002 0.04 0.95 Only HBP 0.05 0.04 0.24
Only medication 0.15 0.09 0.10 Only medication 0.22 0.10 0.03
HBP and antihypertensive medication as individual variables HBP and antihypertensive medication as individual variables
HPB 0.002 0.04 0.95 HPB 0.04 0.04 0.30
Medication 0.15 0.05 <0.01 Medication 0.16 0.05 <0.01
HBPZ high blood pressure (140/90 mmHg); SBPZ systolic blood pressure; DBPZ diastolic blood pressure; FEV1: forced expiratory
volume in one second; FVC: forced vital capacity; Medication: antihypertensive medication.
a Reference category.
b All models are adjusted for gender, age, height, BMI, education level, packyears and respiratory symptoms (cough and sputum
production for at least 3 month per year).
Lung function, hypertension and blood pressure medication 731lung and hence lung compliance and functional residual
capacity fall, causing a decrease in FEV1 and FVC values. In
terms of antihypertensivemedication, there is evidence that
beta-blockers, even relatively cardioselective agents,
produce bronchoconstriction and thereby worsen respira-
tory flows in asthmatic patients.13,14 Apart from that, other
substance classes of antihypertensive medication, as for
example diuretics, calcium channel blockers or ACE inhibi-
tors might have an effect on lung function, too. However, we
cannot investigate the possible effect of different substance
classes, aswedo not have detailed information on the kind of
antihypertensive medication. Thus, we suggest that further
studies with detailed pharmacological data of the drugs used
are necessary to investigate the relationship between lung
function and different therapeutic classes of antihyperten-
sive medication.
From a statistical point of viewwe could clearly show that
HBP in combination with the use of antihypertensive medi-
cation is significantly associated with lower FEV1 and FVC
values. However, the clinical consequences for the indi-
vidual might be relatively small. Nevertheless, they should
not be neglected on the population level. We observed
a mean decline in FEV1 of 150 mL among treated, but not
controlled hypertensive subjects compared to subjects with
no HBP and no antihypertensive medication. This corre-
sponds roughly to the regularly observed decline with aging
over a 8e10 year period.21 Furthermore, the effect size is
similar to the negative effect of smoking on lung function.
Thus, several investigators reported a mean annual decline
in FEV1 of 30e60 mL in persistent smokers depending on the
age of the study population.22e24
When reviewing our results, it must be kept in mind that
20 years ago the indication for antihypertensive treatment
was different from today’s guidelines. Thus, 20 years ago
antihypertensive drugs were prescribed starting from
a blood pressure 160 mmHg systolic or 95 mmHg diastolic,
whereas today the indication for antihypertensive treatment
is a blood pressure 140 mmHg systolic or 90 mmHg dia-
stolic. As a consequence, in our analyses the use of antihy-
pertensive medication might be an indicator for very high
blood pressure. This again is in line with our analysis ofdifferent blood pressure categories, where we could show
that only a very high blood pressure (180/110 mmHg) is
associated with reduced lung function. Furthermore, we
could demonstrate that treated, but not controlled hyper-
tensive subjects had the highest mean systolic and diastolic
blood pressure values. These ineffectively treated hyper-
tensive subjects showed the strongest lung function
impairment. This again suggests the assumption that only the
combination of very high blood pressure and antihyperten-
sive medication is associated with a reduced lung function.
In addition to this, the association between hypertension,
antihypertensive medication and lung function might simply
reflect a confounding effect. Thus, cigarette smoking is
a common risk factor for both impaired lung function and
hypertension. Additionally, BMImight potentially affect lung
function. However, adjustment for these possible
confounders did not influence our results. Moreover, we
could show that the association was not affected by already
existing asthma or chronic bronchitis, defined as cough and
sputum production for at least 3 months per year.
The main strengths of this study are the large sample size
and the population-based setting. Moreover, it is one of few
population-based investigations differentiating between the
effect of blood pressure and of antihypertensive treatment on
lung function in a general adult population. One possible
limitation of this study could be the limited representative
status of the population sample included in our analysis. Thus,
it is difficult to draw conclusion about the general population
from our results. However, selection bias might play a minor
role in association analyses compared to prevalence studies.
Besides, methodological bias might lead to insufficient lung
function measurements. Thus, in patients with hypertension
lung function tests might be stopped earlier, because the
respiratory effort might cause an increase in blood pressure.
Nevertheless, we consider this possible bias unlikely to affect
our results, as all lung function tests were performed by
trained and experienced staff according to international
Standard Operating Procedures. Furthermore, the high prev-
alence of untreated hypertension, which might be partly
ascribed to changes in the indication for antihypertensive
treatment, attracts attention. However, this most probably
732 E. Schnabel et al.reflects the high rate of underdiagnosed and undertreated
people with hypertension in Germany.25 Finally, it has to be
considered that due to the cross-sectional study design we
cannot make a clear statement about the temporal sequence
between hypertension, its medication and lung function.
Thus, several prospective studies found that not only hyper-
tension is a risk factor for reduced lung function, but lower
initial lung function increases the risk of subsequent devel-
opment of hypertension, too.8,9,11,26 Thus, further prospec-
tive studies are necessary to evaluate the temporal sequence
and causality between hypertension, its medical treatment
and lung function.
Conclusion
We speculate that HBP in combination with antihypertensive
treatment and not HBP itself might be associated with
reduced lung function in a general adult population.
However, it has to be taken into account that in our analyses
the antihypertensive medication might just be an indicator
for a very high blood pressure and that only the combination
of very high blood pressure and antihypertensive medication
is associated with lung function impairment.
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